Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2020-12-07 Major Shareholding Noti…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding percentage by a holder ('Handelsbanken Fonder AB') in the issuer ('Infant Bacterial Therapeutics AB'). It explicitly shows the 'Before the transaction' and 'After the transaction' share counts and voting rights, noting the 'Reason for major shareholding notification Sell'. This structure is characteristic of a notification regarding a change in significant ownership, which corresponds to the Major Shareholding Notification category.
2020-12-07 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Infant Bacterial Therapeutics AB for the period 1 January – 30 September 2020. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and management commentary on business performance, risks, and clinical trial progress. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-05 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January 1-September 30, 2020' and contains comprehensive financial statements, including income statements, cash flow data, and management commentary for the specified period. It is not a mere announcement (RPA) as it provides detailed financial tables and analysis. Therefore, it is classified as an Interim/Quarterly Report. 9M 2020
2020-11-05 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period 1 January to 30 June 2020 for Infant Bacterial Therapeutics AB. It contains comprehensive financial statements, balance sheets, cash flow data, management commentary (VD-ord), and details on clinical trials and risks. It is not an announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. H1 2020
2020-08-14 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Report' for the period of January-June 2020, as explicitly stated in the headers. It contains comprehensive financial data, including income statements, balance sheet items, cash flow analysis, and management commentary (CEO message, risk factors, and operational updates). It is not a mere announcement of a report, as it provides the full financial content for the specified period. H1 2020
2020-08-14 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Infant Bacterial Therapeutics AB for the period 1 January – 31 December 2019. It contains comprehensive financial statements, management commentary, operational updates, and financial data tables for the full year and the fourth quarter. It is not a mere announcement of a report, but the report itself, containing substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report (IR) as it covers a specific fiscal period and provides detailed financial performance. FY 2019
2020-08-13 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.